Tessa Therapeutics Names Biopharma Veteran Jeffrey H. Buchalter to Board of Directors
Mr. Buchalter brings over thirty years' experience in the biopharmaceutical industry,with strong corporate leadership and an extensive background in the commercial positioning and development of therapeutics in oncology
SINGAPORE,March 1,2019 -- Tessa Therapeutics,a clinical-stage immunotherapy company focused on autologous and off-the-shelf,allogeneic therapies targeting solid tumors,today announced the appointment of Mr. Jeffrey H. Buchalter as an independent director.
Mr. Buchalter brings over three decades of biopharmaceutical industry experience and has an extensive background in commercialization and drug development in oncology. He has held various chairmanships and senior management positions,including serving as Chairman of the Board,President and Chief Executive Officer of Archimedes Pharma. Prior to joining Archimedes,he wasChairman of the Board,President,and Chief Executive Officerof NASDAQ-listed Enzon Pharmaceuticals,and President,Chief Executive Officer,and Director of Ilex Oncology,Inc.He has also served as a senior executive at Pharmacia,Wyeth and Schering-Plough.
Underscoring his leadership in the industry,Mr. Buchalter received the American Cancer Society's Joseph F. Buckley Memorial Award for his commitment to cancer control and involvement in the oncology pharmaceutical field. At the invitation of former U.S. President George H. W. Bush,he served as Collaborating Partner in the President's National Dialogue on Cancer. He also served as Chairman of the Board of Directors to the National Childhood Cancer Foundation in the United States.
"We are delighted to welcome Jeff to the Tessa board," said Tessa Therapeutics co-founder and CEO,Mr. Andrew Khoo. "His extensive industry leadership experience combined with his deep knowledge of oncology will be a great fit as Tessa moves to our next growth inflection point. Jeff's commercial experience steeped in oncology will be a strong asset to Tessa."
Commenting on his new role,Mr. Buchalter said,"I am pleased to be part of Tessa's growth and development at such a critical stage of the company's growth. I am excited to see the clinical progress Tessa has made in the treatment of solid tumors,using their proprietary technology. The strong operational capabilities of the team as well as Tessa's vibrant culture makethis a compelling opportunity."
Tessa recently announced the addition of Dr. George W. Sledge,Jr.,M.D.,Professor and Chief of Medical Oncology at the Stanford University Medical Center,to its Board of Directors.
About Tessa Therapeutics
Tessa Therapeutics is a clinical-stage immunotherapy company focused on the development of autologous and off-the-shelf,allogeneic therapies targeting solid tumors. Tessa's Virus-Specific T cell (VST) platform harnesses the body's potent anti-viral immune response and has shown compelling results in the treatment of solid tumors.
Tessa is building a portfolio of innovative,next-generation therapies by combining the qualities of VSTs with other immuno-oncology technologies. This includes a rapidly growing pipeline of clinical and pre-clinical autologous programs that target a wide range of cancers,including nasopharyngeal carcinoma (NPC),cervical cancer,oropharyngeal cancer,liver cancer and lung cancer. In addition,Tessa is leveraging its platform to develop an allogeneic therapy to address Epstein-Barr virus (EBV)-associated lymphomas.
Tessa has built up robust operational and supply chain capabilities to successfully deliver T cell therapy treatments to a large patient pool worldwide. Together with the Company's academic,clinical,and commercial research partners,Tessa has created a fully-integrated approach to the treatment of cancer with immunotherapy.
For more information on Tessa,please visit www.tessatherapeutics.com.
Tessa Therapeutics Media Contacts
Gladys Wong
gladyswong@tessatherapeutics.com
+65-6384-0755
Brunswick Group
Will Carnwath,Ben Fry
TessaTherapeutics@brunswickgroup.com
+65-6426-8188
